| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/06/2011 | EP2305291A1 Use of proteasome inhibitors for the treatment of HIV infections |
| 04/06/2011 | EP2305288A2 Acidic insulin preparations with improved stability |
| 04/06/2011 | EP2305282A2 Prevention and treatment of amyloidogenic disease |
| 04/06/2011 | EP2305275A1 Liquid composition comprising cisplatin-coordinating compound |
| 04/06/2011 | EP2305267A2 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| 04/06/2011 | EP2305264A1 Spicamycin derivatives for use in decreasing or preventing pain |
| 04/06/2011 | EP2305263A1 Stabilized amorphous forms of imatinib mesylate |
| 04/06/2011 | EP2305261A1 Methods of manufacturing intraocular implants of alpha-2 adrenergic receptor agonists |
| 04/06/2011 | EP2305259A1 Novel substituted benzimidazole dosage forms and method of using same |
| 04/06/2011 | EP2305257A1 Amonafide salts and compositions comprising same |
| 04/06/2011 | EP2305240A1 Nutrient composition and composition for prevention/mitigation of digestive tract depression |
| 04/06/2011 | EP2305219A1 Pharmaceutical preparations coated with a copolyvidone-containing coating |
| 04/06/2011 | EP2305218A1 Controlled release hydrocodone formulations |
| 04/06/2011 | EP2305217A1 Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 04/06/2011 | EP2305216A1 Two step ultrasound protocol for drug delivery |
| 04/06/2011 | EP2305215A1 Microemulsions of cannabinoid receptor binding compounds |
| 04/06/2011 | EP2305214A1 Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system |
| 04/06/2011 | EP2305213A2 The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 04/06/2011 | EP2305195A1 Drug delivery compositions for improved stability of steroids |
| 04/06/2011 | EP2305194A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2305193A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2305192A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2305191A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2304026A2 Nanoparticle compositions for nucleic acids delivery system |
| 04/06/2011 | EP2304013A1 Dry sanitizing patch for decreasing human pathogen transmission |
| 04/06/2011 | EP2303948A1 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 04/06/2011 | EP2303392A1 Pharmacokinetics of iontophoretic sumatriptan administration |
| 04/06/2011 | EP2303308A2 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis |
| 04/06/2011 | EP2303299A2 Compositions comprising euphorbia prostrata and process of preparation thereof |
| 04/06/2011 | EP2303281A1 Transdermal pharmaceutical compositions comprising danazol |
| 04/06/2011 | EP2303279A1 Topical steroidal formulations |
| 04/06/2011 | EP2303248A1 Dual spray can topical delivery device |
| 04/06/2011 | EP2303247A2 Transdermal system for extended delivery of incretins and incretin mimetic peptides |
| 04/06/2011 | EP2303246A1 Polymersomes, colloidosomes, liposomes, and other species associated with fluidic droplets |
| 04/06/2011 | EP2303245A2 Degradable microcapsules |
| 04/06/2011 | EP2303244A2 Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives |
| 04/06/2011 | EP2303243A1 Oral composition containing an anti-plaque agent of the thienopyridine family in the form of a base |
| 04/06/2011 | EP2303242A1 Pharmaceutical dosage form comprising polymeric carrier composition |
| 04/06/2011 | EP2303241A1 Process for making gastroretentive dosage forms |
| 04/06/2011 | EP2303240A1 Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| 04/06/2011 | EP2303239A1 Directly pressed aliskiren tablets |
| 04/06/2011 | EP2303238A1 Solid dosage formulations of telcagepant potassium |
| 04/06/2011 | EP2303237A2 Preparation method of biodegradable micro-particles containing drugs |
| 04/06/2011 | EP2303236A2 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| 04/06/2011 | EP2303235A2 Stabilization of amorphous drugs using sponge-like carrier matrices |
| 04/06/2011 | EP2303234A1 Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance |
| 04/06/2011 | EP2303233A1 Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
| 04/06/2011 | EP2303232A1 Micronisable form of salmeterol xinafoate |
| 04/06/2011 | EP2303231A1 Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system |
| 04/06/2011 | EP2303230A2 Methods and compositions for enhanced delivery of macromolecules |
| 04/06/2011 | EP2303229A1 Concentrated oxaliplatin solution and its method of preparation |
| 04/06/2011 | EP2303228A1 Fosphenytoin composition |
| 04/06/2011 | EP2303227A2 Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 04/06/2011 | EP2303226A2 Sustained delivery of exenatide and other polypeptides |
| 04/06/2011 | EP2303225A2 Process for preparing a carbapenem antibiotic composition |
| 04/06/2011 | EP2303207A1 Rosorbable membrane implanting methods for reducing adhesions |
| 04/06/2011 | EP2303184A1 Combination treatment of glaucoma |
| 04/06/2011 | EP2303020A1 Preparation of controlled release skeletal muscle relaxant dosage forms |
| 04/06/2011 | EP2275089A9 Preparation of biodegradable microparticles containing a biologically active agent |
| 04/06/2011 | EP2091513B1 Ejection liquid and ejection method |
| 04/06/2011 | EP1965773B1 Oral formulation of anhydrous olanzapine form i |
| 04/06/2011 | EP1878431B1 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
| 04/06/2011 | EP1684715B1 Compositions comprising neramexane |
| 04/06/2011 | EP1663145B1 Oros-push-stick for controlled delivery of active agents |
| 04/06/2011 | EP1596870B2 High dose ibandronate formulation |
| 04/06/2011 | EP1558223B1 Dosage form having an inner core and at least two coating layers |
| 04/06/2011 | EP1467749B1 Thrombin derived peptides for promoting cardiac tissue repair |
| 04/06/2011 | EP1411979B1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 04/06/2011 | EP1404324B2 Prodrugs of gaba analogs, compositions and uses thereof |
| 04/06/2011 | EP1328236B1 Methods of decreasing or preventing pain using spicamycin derivatives |
| 04/06/2011 | CN201782981U 一种提高微生态制剂与相关活性成份安定性及效用的结构 Probiotics with a way to improve the stability and effectiveness of the active ingredient associated structures |
| 04/06/2011 | CN1981869B Compound non-carrier antibacterial eye drops containing practofren and its production |
| 04/06/2011 | CN1981866B DC vaccine for treating chronic hepatitis B |
| 04/06/2011 | CN1942171B Liquids containing suspended glass particles |
| 04/06/2011 | CN1931277B Osteoarthrosis treating Chinese medicine composition and its preparation process |
| 04/06/2011 | CN1859909B Solid dispersions comprising tacrolimus |
| 04/06/2011 | CN1840177B Injection liquid of thymic peptide alpha 1 and preparation method thereof |
| 04/06/2011 | CN1814195B Chinese medicine composition for treating gynecopathy and its preparation method thereof |
| 04/06/2011 | CN1785991B Anti inflammatory detoxication luteolin kind derivative and its preparation method |
| 04/06/2011 | CN1762495B Long acting sustained-release formulation containing dopamine-receptor stimulant medicine and its preparation process |
| 04/06/2011 | CN1730476B Aromatic amine ketone compounds, its synthesis method, pharmaceutical composition containing same and uses |
| 04/06/2011 | CN1660335B Dripping heart pill preparation for alleviating pains of heart and stomach |
| 04/06/2011 | CN1658893B G-type peptides to ameliorate atherosclerosis |
| 04/06/2011 | CN1376146B Solid-state form of celecoxil having enhanced bioavailability |
| 04/06/2011 | CN102006889A Topical combinations comprising an antimycotic agent and an antiviral agent |
| 04/06/2011 | CN102006867A Oral pharmaceutical suspension comprising paracetamol and ibuprofen |
| 04/06/2011 | CN102006863A Film-like composition |
| 04/06/2011 | CN102006862A Compositions comprising weakly basic drugs and controlled-release dosage forms |
| 04/06/2011 | CN102006861A Orally disintegrating tablets |
| 04/06/2011 | CN102006860A Pharmaceutical preparation comprising permethylated cyclodextrin |
| 04/06/2011 | CN102006859A Stable elsamitrucin salt formulations |
| 04/06/2011 | CN102006858A Compositions for the treatment of lice |
| 04/06/2011 | CN102006857A Drug delivery system with stabilising effect |
| 04/06/2011 | CN102002096A Amphipathic compound using somatostatin analogue as target radical and pharmaceutics application thereof |
| 04/06/2011 | CN102000344A Medicament coating composition with masked taste |
| 04/06/2011 | CN102000341A Polyethylene oxide and matrix type surfactant in suppository composition |
| 04/06/2011 | CN102000339A Drug carrier capable of realizing sustained release of drug |
| 04/06/2011 | CN102000335A Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| 04/06/2011 | CN102000333A Immunoglobulin (IgY) antibody oral spray for preventing decayed teeth |
| 04/06/2011 | CN102000325A Pramlintide buccal tablets and preparation method thereof |